nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,days_since_update
NCT04276896,"ClinicalTrials.gov processed this data on June 30, 2020",2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-07-01T09:39:39Z,2020-07-01T09:39:39Z,133
NCT04283461,"ClinicalTrials.gov processed this data on July 21, 2020",2020-02-21,NA,NA,2020-07-16,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"March 16, 2020",Actual,2020-03-16,"May 26, 2020",2020-05-26,"November 22, 2021",Anticipated,2021-11-22,"November 22, 2021",Anticipated,2021-11-22,NA,Interventional,NA,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","Active, not recruiting",NA,Phase 1,120,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,13,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-07-22T08:32:16Z,2020-07-22T08:32:16Z,12
NCT04299724,"ClinicalTrials.gov processed this data on June 30, 2020",2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-07-01T09:37:01Z,2020-07-01T09:37:01Z,144
NCT04313127,"ClinicalTrials.gov processed this data on June 30, 2020",2020-03-15,NA,NA,2020-05-16,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"December 20, 2022",Anticipated,2022-12-20,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,CTCOVID-19,,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","Active, not recruiting",NA,Phase 1,108,Actual,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsorï¼Œinvestigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidentiï¬cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2020-07-01T09:35:22Z,2020-07-01T09:35:22Z,73
NCT04324606,"ClinicalTrials.gov processed this data on July 10, 2020",2020-03-20,NA,NA,2020-07-06,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-08,Actual,"April 23, 2020",Actual,2020-04-23,March 2020,2020-03-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,1090,Actual,University of Oxford,,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-07-13T08:33:05Z,2020-07-13T08:33:05Z,22
NCT04336410,"ClinicalTrials.gov processed this data on July 10, 2020",2020-04-03,NA,NA,2020-07-02,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"April 3, 2020",Actual,2020-04-03,July 2020,2020-07-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1,120,Anticipated,Inovio Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2020-07-12T08:49:49Z,2020-07-12T08:49:49Z,26
NCT04341389,"ClinicalTrials.gov processed this data on June 30, 2020",2020-04-07,NA,NA,2020-05-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 12, 2020",Actual,2020-04-12,May 2020,2020-05-31,"January 31, 2021",Anticipated,2021-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CTII-nCoV,,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Active, not recruiting",NA,Phase 2,508,Actual,"Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-07-01T09:31:59Z,2020-07-01T09:31:59Z,75
NCT04352608,"ClinicalTrials.gov processed this data on June 30, 2020",2020-04-14,NA,NA,2020-04-26,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 13, 2020",Anticipated,2020-12-13,"August 13, 2020",Anticipated,2020-08-13,NA,Interventional,NA,,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years",Recruiting,NA,Phase 1/Phase 2,744,Anticipated,"Sinovac Biotech Co., Ltd",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-07-01T09:30:34Z,2020-07-01T09:30:34Z,93
NCT04357028,"ClinicalTrials.gov processed this data on July 19, 2020",2020-04-19,NA,NA,2020-07-15,2020-04-19,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"July 13, 2020",Anticipated,2020-07-13,July 2020,2020-07-31,"November 1, 2020",Anticipated,2020-11-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,MV-COVID19,,Measles Vaccine in HCW,Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial),Recruiting,NA,Phase 3,200,Anticipated,Kasr El Aini Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-07-21T08:32:04Z,2020-07-21T08:32:04Z,13
NCT04368988,"ClinicalTrials.gov processed this data on June 30, 2020",2020-04-24,NA,NA,2020-05-26,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-27,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"July 31, 2021",Anticipated,2021-07-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-Mâ„¢ Adjuvant In Healthy Subjects",Recruiting,NA,Phase 1,131,Anticipated,Novavax,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-07-01T09:28:37Z,2020-07-01T09:28:37Z,63
NCT04368728,"ClinicalTrials.gov processed this data on July 27, 2020",2020-04-27,NA,NA,2020-07-21,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-23,Actual,"April 29, 2020",Actual,2020-04-29,July 2020,2020-07-31,"January 23, 2023",Anticipated,2023-01-23,"June 28, 2021",Anticipated,2021-06-28,NA,Interventional,NA,,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults","A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVAUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS","Active, not recruiting",NA,Phase 1,32000,Anticipated,BioNTech SE,,22,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2020-07-28T08:31:25Z,2020-07-28T08:31:25Z,7
NCT04380532,"ClinicalTrials.gov processed this data on June 30, 2020",2020-04-29,NA,NA,2020-05-22,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"June 15, 2021",Anticipated,2021-06-15,"May 15, 2021",Anticipated,2021-05-15,NA,Interventional,COVID-19,,Tableted COVID-19 Therapeutic Vaccine,Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Immunitor LLC,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,when become public,non-confidential data,http://immunitor.com,Yes,Free dissemination of published data,2020-07-01T09:27:13Z,2020-07-01T09:27:13Z,67
NCT04380701,"ClinicalTrials.gov processed this data on June 30, 2020",2020-05-06,NA,NA,2020-05-11,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,200,Anticipated,Biontech SE,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-07-01T09:27:12Z,2020-07-01T09:27:12Z,78
NCT04400838,"ClinicalTrials.gov processed this data on July 17, 2020",2020-05-12,NA,NA,2020-07-09,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-13,Actual,"May 28, 2020",Actual,2020-05-28,May 2020,2020-05-31,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,Investigating a Vaccine Against COVID-19,"A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19",Recruiting,NA,Phase 2/Phase 3,10260,Anticipated,University of Oxford,,30,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-07-18T08:48:01Z,2020-07-18T08:48:01Z,19
NCT04405076,"ClinicalTrials.gov processed this data on July 14, 2020",2020-05-13,NA,NA,2020-07-08,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-10,Actual,"May 29, 2020",Actual,2020-05-29,July 2020,2020-07-31,August 2021,Anticipated,2021-08-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 2,600,Actual,"ModernaTX, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-07-15T08:30:02Z,2020-07-15T08:30:02Z,20
NCT04412538,"ClinicalTrials.gov processed this data on June 30, 2020",2020-05-21,NA,NA,2020-06-02,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,September 2021,Anticipated,2021-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,"A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 1/Phase 2,942,Anticipated,Chinese Academy of Medical Sciences,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-07-01T09:23:28Z,2020-07-01T09:23:28Z,56
NCT04405908,"ClinicalTrials.gov processed this data on June 30, 2020",2020-05-25,NA,NA,2020-06-22,2020-05-25,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-23,Actual,"June 19, 2020",Actual,2020-06-19,June 2020,2020-06-30,"March 30, 2021",Anticipated,2021-03-30,"October 20, 2020",Anticipated,2020-10-20,NA,Interventional,NA,,SCB-2019 as COVID-19 Vaccine,"A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.",Recruiting,NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,,15,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-07-01T09:24:14Z,2020-07-01T09:24:14Z,36
NCT04453852,"ClinicalTrials.gov processed this data on July 02, 2020",2020-06-03,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"June 30, 2020",Actual,2020-06-30,June 2020,2020-06-30,"July 1, 2021",Anticipated,2021-07-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,COVAX19,,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Recruiting,NA,Phase 1,40,Anticipated,Vaxine Pty Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-07-06T08:17:53Z,2020-07-06T08:17:53Z,28
NCT04444674,"ClinicalTrials.gov processed this data on July 10, 2020",2020-06-15,NA,NA,2020-07-06,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-08,Actual,"June 24, 2020",Actual,2020-06-24,July 2020,2020-07-31,December 2021,Anticipated,2021-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",Recruiting,NA,Phase 1/Phase 2,2000,Anticipated,"University of Witwatersrand, South Africa",,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,within 1 year of trial completion,Any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.,NA,Yes,"The data accumulated from this study will be stored at RMPRU/ Wits. In collaboration with UK collaborators, we aim to make the data available, within one year of completion of the study to any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.
De-identified data will be shared. Related trial documents will be available (protocol, ICFs, statistical analysis plan)",2020-07-13T08:30:43Z,2020-07-13T08:30:43Z,22
NCT04445194,"ClinicalTrials.gov processed this data on July 02, 2020",2020-06-16,NA,NA,2020-06-30,2020-06-21,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-02,Estimate,"June 22, 2020",Actual,2020-06-22,May 2020,2020-05-31,"September 20, 2021",Anticipated,2021-09-20,"July 21, 2021",Anticipated,2021-07-21,NA,Interventional,NA,,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age",Recruiting,NA,Phase 1,50,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-07-07T08:11:38Z,2020-07-07T08:11:38Z,28
NCT04449276,"ClinicalTrials.gov processed this data on July 02, 2020",2020-06-18,NA,NA,2020-06-30,2020-06-23,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"June 18, 2020",Actual,2020-06-18,June 2020,2020-06-30,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","A Phase 1, Partially Blind, Placebo-controlled, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults",Recruiting,NA,Phase 1,168,Anticipated,CureVac AG,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-07-06T08:18:51Z,2020-07-06T08:18:51Z,28
NCT04450004,"ClinicalTrials.gov processed this data on July 19, 2020",2020-06-18,NA,NA,2020-07-14,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-16,Actual,"July 10, 2020",Actual,2020-07-10,July 2020,2020-07-31,"April 30, 2021",Anticipated,2021-04-30,"September 12, 2020",Anticipated,2020-09-12,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age",Recruiting,NA,Phase 1,180,Anticipated,Medicago,,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-07-21T08:29:44Z,2020-07-21T08:29:44Z,14
NCT04445389,"ClinicalTrials.gov processed this data on June 30, 2020",2020-06-19,NA,NA,2020-06-24,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-26,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"June 17, 2022",Anticipated,2022-06-17,"March 17, 2021",Anticipated,2021-03-17,NA,Interventional,NA,,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects",Recruiting,NA,Phase 1/Phase 2,190,Anticipated,"Genexine, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-07-01T09:19:53Z,2020-07-01T09:19:53Z,34
NCT04445428,"ClinicalTrials.gov processed this data on July 19, 2020",2020-06-22,NA,NA,2020-07-15,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"July 15, 2020",Actual,2020-07-15,July 2020,2020-07-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,OPV as Potential Protection Against COVID-19,Oral Polio Vaccine as Potential Protection Against COVID-19: A Cluster-randomised Trial in Guinea-Bissau,Enrolling by invitation,NA,Phase 4,3400,Anticipated,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Provided request, data can be made available",2020-07-21T08:29:54Z,2020-07-21T08:29:54Z,13
NCT04460703,"ClinicalTrials.gov processed this data on July 24, 2020",2020-07-02,NA,NA,2020-07-18,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-18,2020-07-21,Actual,"July 3, 2020",Actual,2020-07-03,July 2020,2020-07-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,"COVID-19 Vaccine Messaging, Part 1","Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1",Completed,NA,N/A,4000,Actual,Yale University,,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After publication,Anonymized data and analysis code will be posted in a public replication archive,NA,Yes,Anonymized data and analysis code will be posted in a public replication archive after publication.,2020-07-26T08:41:02Z,2020-07-26T08:41:02Z,10
NCT04466085,"ClinicalTrials.gov processed this data on July 27, 2020",2020-07-08,NA,NA,2020-07-24,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Estimate,"July 12, 2020",Actual,2020-07-12,July 2020,2020-07-31,"December 15, 2021",Anticipated,2021-12-15,"September 15, 2021",Anticipated,2021-09-15,NA,Interventional,NA,,Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 2,900,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-07-28T08:29:50Z,2020-07-28T08:29:50Z,4
NCT04470609,"ClinicalTrials.gov processed this data on July 17, 2020",2020-07-13,NA,NA,2020-07-13,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"July 10, 2020",Actual,2020-07-10,July 2020,2020-07-31,November 2021,Anticipated,2021-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged â©¾60 Years",Enrolling by invitation,NA,Phase 1/Phase 2,471,Anticipated,Chinese Academy of Medical Sciences,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-07-19T08:38:51Z,2020-07-19T08:38:51Z,15
NCT04475302,"ClinicalTrials.gov processed this data on July 27, 2020",2020-07-16,NA,NA,2020-07-21,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-23,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,May 2021,Anticipated,2021-05-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India,Recruiting,NA,Phase 3,2175,Anticipated,"Tuberculosis Research Centre, India",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-07-28T08:29:39Z,2020-07-28T08:29:39Z,7
